FDA DEVICE FACTS
Universal Cylinder Applicator Family
Varian Medical Systems, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Universal Segmented Cylinder Applicator Set and Universal Stump Applicator Set are intended for cancer treatment of the vagina, vaginal stump and rectum using HDR or PDR brachytherapy. The Universal Cervix Probe Sets in combination with the Universal Segmented Cylinder Applicator Set and the Universal Stump Applicator Set are intended for cancer treatment of the vagina, vaginal stump, cervix, uterus and endometrium using HDR or PDR brachytherapy. The Universal Titanium Cervix Probe Sets in combination with the Universal Segmented Cylinder Applicator Set and the Universal Stump Applicator Set are intended for cancer treatment of the vagina, vaginal stump, cervix, uterus and endometrium using HDR or PDR brachytherapy.
The Universal Multi-Channel Cylinder Set is indicated for use for cancer treatment of the vagina, vaginal stump, cervix, uterus, endometrium and rectum using HDR or PDR brachytherapy. The Universal Cervix Probe Sets in combination with the Universal Multi-Channel Cylinder Set are indicated for use for cancer treatment of the vagina, cervix, uterus and endometrium using HDR or PDR brachytherapy. The Universal Titanium Cervix Probe Sets in combination with the Universal Multi-Channel Cylinder Set are indicated for use for cancer treatment of the vagina, cervix, uterus and endometrium using HDR or PDR brachytherapy.
The Universal Interstitial Cylinder Set is indicated for use for cancer treatment of the vagina, vaginal stump, cervix, uterus and endometrium using intracavitary and interstitial HDR or PDR brachytherapy. The Universal Cervix Probe Sets in combination with the Universal Interstitial Cylinder Set are indicated for use for cancer treatment of the vagina, cervix, uterus and endometrium using HDR or PDR brachytherapy. The Universal Titanium Cervix Probe Sets in combination with the Universal Interstitial Cylinder Set are indicated for use for cancer treatment of the vagina, cervix, uterus and endometrium using HDR or PDR brachytherapy.
COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE The new device, referred to as the “subject device” throughout this submission, is the Universal Cylinder Applicator Family with added Universal Multi-Channel Cylinder (UMC) and Universal Interstitial Cylinder (UIC) Applicator Sets. At a high level, both the applicators of the predicate device and the applicators added in the subject device are based on the same technological characteristics:
• All UCAF applicators and probes are designed for use with a Varian afterloader to deliver HDR and PDR brachytherapy for gynaecological and rectal cases.
• All UCAF applicators are used in the same CT and MR environment, and with the same cervix probes.
The following technological differences exist between the applicators of the subject and the predicate devices:
• With the addition of UIC applicators, UCAF can be used for intracavity and interstitial brachytherapy.
• UMC and UIC applicators have multiple peripheral channels that allow for asymmetric dose shaping to improve target volume coverage while reducing dose to organs at risk.
• All UCAF applicators and probes are now compatible with Bravos afterloader. Further, 25-mm UMC and UIC applicators are compatible with Kelowna GYN template.
• UMC and UIC applicators are composed of PEEK, while predicate applicators are composed of PPSU.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。